Pinned Tweet
There are no stories without meaning. Begin small, begin from the end or the beginning. Tell me a story.
amalia negreponti retweeted
Austin Texas sounds like an Eastern European city that just overthrew a dictator
amalia negreponti retweeted
Genuinely shocked that Trump’s platform to raise prices, go to war for no reason, and gun down nurses in the streets didn’t resonate with the electorate
amalia negreponti retweeted
Insanely, horribly bad night for Elon Musk, who not only wasted half a billion but will have a Congress who hates him and an entire texas state government who loathes him
amalia negreponti retweeted
I believe that parents should be able to screen their embryos for certain types of diseases that irreparably impair quality of life, and yet, this particular effort makes me feel a surge of moral agony. We will not save anything worth saving in the human experience if we go down a path of excluding those capable of emotional suffering from existence. What we owe to people who are suffering is not to erase them, but to give them our best efforts to heal them.
amalia negreponti retweeted
My mother was a philosophy professor in Oxford ... and at age 8 I was fond of declaring "If there's one thing I'll never be when I'm grown up it's a philosopher!"
Well, decades later, my science led me to figure out some rather interesting things in philosophy ... and now there's a book of my philosophical essays just published.
amazon.com/Ultimately-There-…
all of these are wild, but the fact that a cell can loses its tumor-suppressing function even though sequencing the gene would still show a normal (wild-type) sequence is killing me
COOL FACTS ABSOLUTELY NO ONE HAS CARED ABOUT THIS WEEK (ZERO POLITICS, ZERO SCIENCE DRAMA, ZERO AI, ZERO NEGATIVITY) while I avoid packing:
-FREAKING NEURONS make the aggrecans/proteoglycans for their own perineuronal nets NOT GLIA and it's predominantly inhibitory neurons BUT it has to be expressed by excitatory neurons in order for critical period closure
-XIST (x inactive specific transcript) that keeps the second X inactive (but like only partially and dynamically depending on tissue type) is PROTEIN CODING IN BIRDS AND FISH AND IN FISH IT CONTROLS DEVELOPMENTAL AXES VIA AN E3 LIGASE
-sometimes cancer cells just pop a tumor suppressor onto the inactive x and xist just zambonis over that nonsense in cis
-WE OWE LIKE OUR ENTIRE UNDERSTANDING OF RNA BIOLOGY FROM SPLICING TO THE SPLICEOSOME TO SOME TRNA STUFF TO NUCLEOLAR BIOLOGY TO AUTOIMMUNE PATIENTS PROVIDING THEIR SERA IN THE 70S AND 80S FOR AUTOANTIBODIES AGAINST THE RELEVANT RIBONUCLEOPROTEINS
-the original cells ANA tests were used on were HEp-2 cells which turned out to be HeLa cells the whole time and do absolutely fucked things with their sex chromosomes
I'm not rereading for typos, yolo
amalia negreponti retweeted
Customer B has been revealed. Anthropic is SpaceX's largest single customer, overtaking NASA and the Pentagon for the first time. 34.5% of SpaceX's revenue last quarter was from compute-as-a-service to Dario Amodei, and Anthropic has committed to spending up to $120.5 billion through 2029. He will be paying Elon $3.1 billion a month starting in December 2026.
amalia negreponti retweeted
>be benjamine liu
>immigrate from taiwan to california at age 2
>grow up in thousand oaks
>go to yale
>study computational biology at cambridge
>become a rhodes scholar at oxford
>use AI to research alzheimer’s and parkinson’s
>try pitching new drugs to pharma companies
>get rejected
>“we have more drugs than we can afford to develop”
>realize drug discovery isn’t the bottleneck clinical trials are
>everyone is using AI to discover new drugs
>bet on developing them faster instead
>cold email legendary investor michael moritz
>get a reply in 28 minutes
>get a $2.25M check
>cofound trialspark in 2016
>rebrand to formation bio
>partner with openai and sanofi
>raise $372M series D led by a16z
>build a $1.8B AI pharma company
>raise over $600M to make medicine move faster
Today we’re announcing the $600M Formation Bio Drug Development Accelerator Fund.
@lintaho and I started @FormationBio because we believed the biggest bottleneck in bringing new medicines to patients wasn’t drug discovery, but drug development.
As AI dramatically accelerates discovery, that bottleneck is only becoming more acute. Without the capital and capacity to advance promising drugs through clinical trials, much of that progress won’t translate into medicines for patients.
Our new Fund brings together dedicated capital, drug development expertise, and AI-powered development capabilities to acquire promising drugs and advance them through the clinic.
amalia negreponti retweeted
It's still such an adorable moment when the agent casually clicks the "I am not a robot" checkbox
amalia negreponti retweeted
Tyler Cowen:
'I am not even sure what to say at this point. We need a radical revaluation of this work, and of the associated policy arguments. More generally, this is only a single step in the story of how AI is going to revise economic science, and indeed past research more generally. As I stress in many of my recent talks, there will be significant gains and losses in status, with the losses often outweighing the gains. I see this as one of those cases.'
Errors in the research of Emmanuel Saez and Gabriel Zucman marginalrevolution.com/margi…
amalia negreponti retweeted
OPENAI PLANS TO BUY GOOGLE’S AI CHIPS, THOUGH THE FINANCIAL TERMS AND OTHER DETAILS OF THE PLANNED PURCHASE COULDN’T BE LEARNED - THE INFORMATION
amalia negreponti retweeted
everyone posting their generational fumbles for not joining anthropic or openai
i've been in sf since 2018. was at the first anthropic holiday party. here's me and ilya (photo titled 3 GOATs) in 2019 lol, yeah i prob fumbled both labs
it's easy to look back and calculate the equity you could've had. harder to remember you were busy living a life, following your own curiosities, building things you believed in.
the real generational fumble might be spending your life wishing you'd lived someone else's.
and congrats to my ant friends, what a time ❤️🔥
amalia negreponti retweeted
Sam Altman's one-person company prediction is coming true. Anthropic just bought one. The founder of Mithril Medicine used Claude to take a muscular dystrophy antibody treatment from concept to proof-of-principle in mice in 18 months, with just himself, Claude, and part-time consultants. The technical report is great. I will quote:
'The week opened with the handover of two cell-based assays, cell adhesion and flow cytometry, within our team, while eleven questions remained open with the assay CRO. In two sentences, one of us asked Claude to review the latest emails between the outgoing assay lead and the assay CRO and to recommend next steps for the handover, and gave it the link to the handover folder. Claude returned a bottom line after 96s and a full plan with five drafted emails after 18 min. For the full plan it read six email threads, the handover folder, two slide decks and two reports, all in the mailbox and file store to which we had given it access. Four working days later, nine of the eleven questions had an answer in writing and the other two had been left to pilot experiments. The adhesion screen was thereby set out in writing. The CRO drew the plate map to the format that our team had requested, Claude compiled the run order and the material calculation from the production data, and one of us reviewed and approved them.
On day 4, the production CRO delivered its data package, a report of 341 pages, which one of us forwarded to Claude in two sentences, with the request to review it, share observations and recommend next steps. Claude returned a bottom line after 2 min 40s and, once it had read every page, a visual synthesis of all 113 constructs after 7 min 53s. The synthesis arranged the constructs on the grid of 14 by 8 arms. Claude marked 82 constructs for screening as is, seven for additional polishing, and the 24 constructs of three laminin-binding arms to be held back from the cell-based assays on production criteria. Each of the 113 constructs thus had a proposed next step in less than 8 min.
Claude had recommended binding kinetics for all 113 con-structs, and on day 7 one of us challenged this plan. Claude defended it within 27s, arguing that affinity would show whether the three arms merit further work. One of us overruled this recommendation and set the three arms aside on production criteria. Their material remains in storage. Four minutes later, Claude had revised its memo, the working page, the run order and three unsent drafts from 113 to 89 constructs. It had also applied the ruling to three dependent steps in the unsent drafts, each flagged for our veto. The exchange took 7 min 36s from challenge to new plan, and every affected email was still an unsent draft. After the ruling, eight emails drafted by Claude went out on the same day to three CROs and a consultant.
Over the whole week, Claude drafted 17 emails, each in answer to a request from one of us, and we sent 12 of them, each after editing. With its drafts, Claude listed 41 points, such as tube fills, shipping conditions, recipients and assay settings, for which it had found no written statement of ours, so that we could confirm, change or strike each before sending. We kept some, struck others and changed one. Among the passages that we kept were proposals for controls. One draft proposed a comparison of polished and unpolished material on one sensor chip, to size the error that impurities cause in the rest of the panel. Another requested a buffer control diluted like the most dilute sample, so that any effect of the buffer appears at its largest. These proposals concerned the measurement of constructs that had already been produced, and each reached a CRO only after one of us had reviewed and approved it.

































